Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
141 hedge funds and large institutions have $738M invested in Astria Therapeutics in 2025 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 33 closing their positions.
94% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 33
81% more capital invested
Capital invested by funds: $409M → $738M (+$329M)
23% more funds holding
Funds holding: 115 → 141 (+26)
6% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 31
0.53% less ownership
Funds ownership: 99.54% → 99.02% (-0.53%)
41% less call options, than puts
Call options by funds: $274K | Put options by funds: $466K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$45.1M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$41M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$21.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$61.4M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$36.1M |
| 3 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$29.9M |
| 4 |
Millennium Management
New York
|
-$29.9M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$25.9M |
ATXS Hedge Fund Activity: Q4 2025 in Review
141 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2025, worth a combined $738M — up 81% from $409M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new ATXS positions and 33 closed out — a net gain of 31 holders — while 33 added to existing stakes and 31 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $45.1M. The largest seller was Fidelity Investments, cutting an estimated $61.4M.
- 141 institutional investors held Astria Therapeutics (ATXS) as of Q4 2025, up from 115 in Q3 2025.
- Funds reported $738M of Astria Therapeutics stock for Q4 2025, up 81% quarter-over-quarter.
- 64 funds opened new Astria Therapeutics positions in Q4 2025 and 33 closed out, a net change of +31 holders.
- The largest Astria Therapeutics buyer in Q4 2025 was Glazer Capital LLC, an estimated $45.1M added.
- The largest Astria Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $61.4M sold.
Based on aggregated 13F filings for Q4 2025.